ZBIO News and Press, ProShares UltraPro Short NASDAQ Biotechnology From 02/08/19

By Andy Acker, CFA & Daniel Lyons, Ph.D., CFA & John Scotti, D.Phil. The biotech industry is experiencing a renaissance, with the U.S. approving a record number of novel therapies in 2018. But not all drugs are created equal, say members of the Janus Henderson Global Life Sciences...

2018 seems to be ending on a bad note in the markets. December is setting the wrong kind of records, and Q4 has been a bumpy one in general. This is what happens in the stock market sometimes, but it's been easy to forget over the decade-long bull market. We're using the end of the year as a...

By Ethan Lovell Portfolio Manager Ethan Lovell discusses a new proposal to overhaul drug pricing in Medicare Part B and what it could mean for drug manufacturers. Key Takeaways A proposal to lower drug costs would align Medicare Part B drug prices with prices outside the U.S., wher...

We've turned the page to November, and investors across the globe may feel a bit of unconscious relief. Stock markets do fluctuate, but months like October are never fun. And that has been especially acute in biotech. Leading ETFs like IBB and XBI dropped ~15% and 18% respectively in October...

Speaking at the Department of Health & Human Services, the president says both consumers and the government can save money if drugs were priced along the lines of that of other countries (i.e., Canada). More news on: iShares Nasdaq Biotechnology ETF, Health Care Select Sect SPDR ETF,...

By Evan McCulloch, Senior Vice President, Director of Research Franklin Equity Group ® Portfolio Manager, Franklin Biotechnology Discovery Fund Franklin Equity Group's Evan McCulloch explains why higher rates of drug utilization and healthcare spending are lending support to the b...